SCHEMBL21224166

SCHEMBL21224166

NCCCC[C@H](NC(=O)c1ccccc1)C(=O)Nc1nc(-c2ccccc2)cs1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 8/20 0.58
HDAC1 Q13547 7/20 0.58
HDAC4 P56524 7/20 0.57
HDAC3 O15379 6/20 0.57
HDAC7 Q8WUI4 6/20 0.57
HDAC2 Q92769 6/20 0.57
HDAC10 Q969S8 6/20 0.57
HDAC11 Q96DB2 6/20 0.57
HDAC8 Q9BY41 6/20 0.57
HDAC9 Q9UKV0 6/20 0.57
HDAC5 Q9UQL6 6/20 0.57
SCD O00767 1/20 0.57
PARP1 P09874 1/20 0.54
EP300 Q09472 1/20 0.53
MEF2D Q14814 1/20 0.53
LMNA P02545 2/20 0.53
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21224170 1.00 HDAC6 (0.58) HDAC6HDAC1HDAC4HDAC3HDAC7
SCHEMBL5472600 0.90 HDAC6 (0.61) HDAC6HDAC1HDAC4HDAC3HDAC7
SCHEMBL5366535 0.89 HDAC6 (0.60) HDAC6HDAC1HDAC4HDAC3HDAC7
SCHEMBL21241916 0.88 SCD (0.58) HDAC6HDAC1HDAC4HDAC3HDAC7
SCHEMBL21241784 0.88 SCD (0.58) HDAC6HDAC1HDAC4HDAC3HDAC7
SCHEMBL28528489 0.88 HDAC6 (0.58) HDAC6HDAC1HDAC4HDAC3HDAC7
SCHEMBL28528487 0.87 HDAC6 (0.56) HDAC6HDAC1HDAC4HDAC3HDAC7
SCHEMBL23729256 0.86 HDAC6 (0.49) HDAC6HDAC1HDAC4HDAC3HDAC7
SCHEMBL21241915 0.86 HDAC6 (0.57) HDAC6HDAC1HDAC4HDAC3HDAC7
SCHEMBL21241793 0.86 HDAC6 (0.57) HDAC6HDAC1HDAC4HDAC3HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12383560-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-08-12 US disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-11497752-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2022-11-15 US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 US disclosed
CN-112153984-A Compound and use thereof 福宏治疗公司 2020-12-29 CN disclosed
EP-3746124-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2020-12-09 EP disclosed
WO-2019152437-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2019-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB HDAC6 86/4885HDAC1 242/4885HDAC4 152/4885
US-12383560-B2 Compounds and uses thereof VHL, CLN6, TFEB HDAC6 86/4885HDAC1 242/4885HDAC4 152/4885
US-11497752-B2 Compounds and uses thereof VHL, CLN6, TFEB HDAC6 86/4885HDAC1 242/4885HDAC4 152/4885
US-20210038611-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB HDAC6 86/4885HDAC1 242/4885HDAC4 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.